Literature DB >> 30040714

A Three-Factor Structure of Cognitive Functioning Among Unimpaired Carriers and Non-Carriers of Autosomal-Dominant Alzheimer's Disease.

Edmarie Guzmán-Vélez1, Sehily Jaimes1, Daniel C Aguirre-Acevedo2,3, Daniel J Norton1, Kathryn V Papp4,5, Rebecca Amariglio4,5, Dorene Rentz4,5, Ana Baena3, Eliana Henao3, Victoria Tirado3, Claudia Muñoz3, Margarita Giraldo3, Reisa A Sperling4,5, Francisco Lopera3, Yakeel T Quiroz1,3,5.   

Abstract

BACKGROUND: There is a need to find cognitive markers that can help identify individuals at risk for Alzheimer's disease (AD), and that can be used to reliably measure cognitive decline.
OBJECTIVE: We tested whether a theoretically driven three-factor structure would characterize cognitive functioning in individuals who are genetically-determined to develop AD due to a mutation in Presenilin-1 (PSEN1) gene. We also examined whether these factors could distinguish cognitively unimpaired PSEN1 mutation carriers from age-matched non-carrier family members.
METHODS: 1,395 cognitively unimpaired members of a Colombian kindred with the PSEN1 E280A mutation were included in the study. A confirmatory factor analysis examined the fit of the three-factor model comprising episodic memory (MMSE memory recall, CERAD-COL Word list recall, and Constructional praxis recall), executive function (Phonemic fluency and WCST perseverative errors), and psychomotor processing speed (TMT-A and WAIS-III Digit Symbol).
RESULTS: The three-factor model provided an excellent fit for all participants (p = 0.24; RMSEA = 0.01). Further, the episodic memory (p = 0.0004, d = 0.25) and executive functioning (p = 0.001, d = 0.18) factors distinguished cognitively unimpaired carriers from non-carriers. The episodic memory factor provided the earliest indication of preclinical cognitive decline at 35 years of age, nine years before individuals' estimated age of clinical onset.
CONCLUSIONS: The three theoretically derived cognitive factors provide a reliable measure of cognition and may be useful for the early detection of AD, as well as for measuring disease progression. However, longitudinal studies are needed to confirm that these factors can be used to track the progression of cognitive decline in preclinical AD.

Entities:  

Keywords:  Confirmatory factor analysis; cognitive factors; contstartabstract; episodic memory; executive function; preclinical Alzheimer’s disease; processing speed

Mesh:

Substances:

Year:  2018        PMID: 30040714      PMCID: PMC6942670          DOI: 10.3233/JAD-180078

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  37 in total

1.  Early pathologic amyloid induces hypersynchrony of BOLD resting-state networks in transgenic mice and provides an early therapeutic window before amyloid plaque deposition.

Authors:  Disha Shah; Jelle Praet; Amira Latif Hernandez; Corinna Höfling; Cynthia Anckaerts; Frédérique Bard; Markus Morawski; Jan R Detrez; Els Prinsen; Alessandro Villa; Winnok H De Vos; Adriana Maggi; Rudi D'Hooge; Detlef Balschun; Steffen Rossner; Marleen Verhoye; Annemie Van der Linden
Journal:  Alzheimers Dement       Date:  2016-04-21       Impact factor: 21.566

2.  Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease: A Retrospective Cohort Study.

Authors:  Daniel C Aguirre-Acevedo; Francisco Lopera; Eliana Henao; Victoria Tirado; Claudia Muñoz; Margarita Giraldo; Shrikant I Bangdiwala; Eric M Reiman; Pierre N Tariot; Jessica B Langbaum; Yakeel T Quiroz; Fabian Jaimes
Journal:  JAMA Neurol       Date:  2016-04       Impact factor: 18.302

3.  Executive functioning and risk for Alzheimer's disease in the cognitively intact: Family history predicts Wisconsin Card Sorting Test performance.

Authors:  Kathleen E Hazlett; Christina M Figueroa; Kristy A Nielson
Journal:  Neuropsychology       Date:  2015-01-26       Impact factor: 3.295

4.  [Mild cognitive impairment and Alzheimer's disease: an investigation of the CERAD-NP test battery].

Authors:  S Barth; P Schönknecht; J Pantel; J Schröder
Journal:  Fortschr Neurol Psychiatr       Date:  2005-10       Impact factor: 0.752

5.  Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

Authors:  Courtney L Sutphen; Mateusz S Jasielec; Aarti R Shah; Elizabeth M Macy; Chengjie Xiong; Andrei G Vlassenko; Tammie L S Benzinger; Erik E J Stoops; Hugo M J Vanderstichele; Britta Brix; Heather D Darby; Manu L J Vandijck; Jack H Ladenson; John C Morris; David M Holtzman; Anne M Fagan
Journal:  JAMA Neurol       Date:  2015-09       Impact factor: 18.302

6.  Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.

Authors:  Emily C Edmonds; Katherine J Bangen; Lisa Delano-Wood; Daniel A Nation; Ansgar J Furst; David P Salmon; Mark W Bondi
Journal:  J Int Neuropsychol Soc       Date:  2016-11       Impact factor: 2.892

7.  Event-related potential markers of brain changes in preclinical familial Alzheimer disease.

Authors:  Y T Quiroz; B A Ally; K Celone; J McKeever; A L Ruiz-Rizzo; F Lopera; C E Stern; A E Budson
Journal:  Neurology       Date:  2011-07-20       Impact factor: 9.910

Review 8.  Cognitive reserve in ageing and Alzheimer's disease.

Authors:  Yaakov Stern
Journal:  Lancet Neurol       Date:  2012-11       Impact factor: 44.182

9.  Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers.

Authors:  Yakeel T Quiroz; Chantal E Stern; Eric M Reiman; Michael Brickhouse; Adriana Ruiz; Reisa A Sperling; Francisco Lopera; Bradford C Dickerson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-11-07       Impact factor: 10.154

Review 10.  Disease-modifying therapies for Alzheimer disease: challenges to early intervention.

Authors:  Jeffrey L Cummings; Rachelle Doody; Christopher Clark
Journal:  Neurology       Date:  2007-10-16       Impact factor: 9.910

View more
  6 in total

1.  Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers.

Authors:  Edmarie Guzmán-Vélez; Jairo Martínez; Kate Papp; Ana Baena; Clara Vila-Castelar; Arabiye Artola; Aaron P Schultz; Yamile Bocanegra; Justin Sanchez; Dorene Rentz; Pierre N Tariot; Eric M Reiman; Reisa Sperling; Keith A Johnson; Francisco Lopera; Yakeel T Quiroz
Journal:  Neurology       Date:  2020-07-01       Impact factor: 9.910

Review 2.  Past, present and future role of retinal imaging in neurodegenerative disease.

Authors:  Amir H Kashani; Samuel Asanad; Jane W Chan; Maxwell B Singer; Jiong Zhang; Mona Sharifi; Maziyar M Khansari; Farzan Abdolahi; Yonggang Shi; Alessandro Biffi; Helena Chui; John M Ringman
Journal:  Prog Retin Eye Res       Date:  2021-01-15       Impact factor: 19.704

3.  Effects of gene mutation and disease progression on representative neural circuits in familial Alzheimer's disease.

Authors:  Meina Quan; Tan Zhao; Yi Tang; Ping Luo; Wei Wang; Qi Qin; Tingting Li; Qigeng Wang; Jiliang Fang; Jianping Jia
Journal:  Alzheimers Res Ther       Date:  2020-01-14       Impact factor: 6.982

4.  Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease.

Authors:  Daniel J Norton; Mario A Parra; Reisa A Sperling; Ana Baena; Edmarie Guzman-Velez; David S Jin; Nicholas Andrea; Juna Khang; Aaron Schultz; Dorene M Rentz; Enmanuelle Pardilla-Delgado; Joshua Fuller; Keith Johnson; Eric M Reiman; Francisco Lopera; Yakeel T Quiroz
Journal:  Alzheimers Res Ther       Date:  2020-08-21       Impact factor: 6.982

5.  The congruency of neuropsychological and F18-FDG brain PET/CT diagnostics of Alzheimer's Disease (AD) in routine clinical practice: insights from a mixed neurological patient cohort.

Authors:  Sascha Hansen; Jana Keune; Kim Küfner; Regina Meister; Juliane Habich; Julia Koska; Stefan Förster; Patrick Oschmann; Philipp M Keune
Journal:  BMC Neurol       Date:  2022-03-09       Impact factor: 2.474

6.  Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease.

Authors:  Ophir Keret; Adam M Staffaroni; John M Ringman; Yann Cobigo; Sheng-Yang M Goh; Amy Wolf; Isabel Elaine Allen; Stephen Salloway; Jasmeer Chhatwal; Adam M Brickman; Dolly Reyes-Dumeyer; Randal J Bateman; Tammie L S Benzinger; John C Morris; Beau M Ances; Nelly Joseph-Mathurin; Richard J Perrin; Brian A Gordon; Johannes Levin; Jonathan Vöglein; Mathias Jucker; Christian la Fougère; Ralph N Martins; Hamid R Sohrabi; Kevin Taddei; Victor L Villemagne; Peter R Schofield; William S Brooks; Michael Fulham; Colin L Masters; Bernardino Ghetti; Andrew J Saykin; Clifford R Jack; Neill R Graff-Radford; Michael Weiner; David M Cash; Ricardo F Allegri; Patricio Chrem; Su Yi; Bruce L Miller; Gil D Rabinovici; Howard J Rosen
Journal:  Alzheimers Dement (Amst)       Date:  2021-07-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.